Nurix Therapeutics, Inc.
NRIX
Updated: 23/09/2026, 06:37:05
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
No summaries found.
- Share price
- $25.67
- Market cap
- $2.66B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Arthur T. Sands
- Employees
- 317
- IPO date
- 24/07/2020
- Beta
- 1.802
- Last dividend
- $0.00
- Day range
- $25.23 – $25.96
- 52-week range
- $8.20 – $28.23
- 1-day performance
- 1.02%
- 1-year performance
- 213.24%
- Current drawdown (1Y)
- -9.07%
- CIK
- 0001549595
- CUSIP
- 67080M103
- ISIN
- US67080M1036
- Created
- 07/12/2025, 05:29:37
- Last update
- 23/09/2026, 06:37:05
Track Nurix Therapeutics, Inc. with an AI analyst
See which prediction-market events move NRIX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases Transcript
Seeking Alpha • STOCK • 08/06/2026, 18:58:35
Nurix Therapeutics (NASDAQ:NRIX) Sees Significant Upside Potential Following Roche Partnership
Market Data • Market Data • 08/06/2026, 18:12:36
Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 22/05/2026, 20:20:44
Nurix Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire • STOCK • 13/05/2026, 09:00:00
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
GlobeNewsWire • STOCK • 22/04/2026, 09:00:00
Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Seeking Alpha • STOCK • 17/04/2026, 08:51:47
Stock Article
Market Data • Market Data • 09/04/2026, 21:00:02
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide
Seeking Alpha • STOCK • 09/04/2026, 17:49:00
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research • STOCK • 08/04/2026, 10:12:05
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
GlobeNewsWire • STOCK • 08/04/2026, 08:00:00
Nurix Therapeutics to Participate in Upcoming Investor Conference
GlobeNewsWire • STOCK • 07/04/2026, 09:00:00
Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?
Zacks Investment Research • STOCK • 26/03/2026, 11:16:19